Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium
Annemarie Rosan Kreeftmeijer-Vegter,Perry J.J. van Genderen,Leo G. Visser,Wouter F W Bierman,Jan Clerinx,Cees K. W. van Veldhuizen,Peter J. de Vries +6 more
Reads0
Chats0
TLDR
Data from the named patient programme demonstrate that IV artesunate is effective and well-tolerated in European travellers lacking immunity, however, increased attention needs to be paid to the possible development of haemolytic anaemia 2-3 weeks after start of treatment.Abstract:
Intravenous (IV) artesunate is the treatment of choice for severe malaria. In Europe, however, no GMP-manufactured product is available and treatment data in European travellers are scarce. Fortunately, artesunate became available in the Netherlands and Belgium through a named patient programme. This is the largest case series of artesunate treated patients with severe malaria in Europe. Hospitalized patients treated with IV artesunate between November 2007 and December 2010 in the Netherlands and Belgium were retrospectively evaluated. Patient characteristics, treatment and clinical outcome were recorded on a standardized form and mortality, parasite clearance times and the occurrence of adverse events were evaluated. Of the 68 treated patients, including 55 with severe malaria, two patients died (2/55 = 3.6%). The mean time to 50% parasite clearance (PCT50), 90% and 99% were 4.4 hours (3.9 - 5.2), 14.8 hours (13.0 - 17.2), and 29.5 hours (25.9 - 34.4) respectively. Artesunate was well tolerated. However, an unusual form of haemolytic anaemia was observed in seven patients. The relationship with artesunate remains uncertain. Data from the named patient programme demonstrate that IV artesunate is effective and well-tolerated in European travellers lacking immunity. However, increased attention needs to be paid to the possible development of haemolytic anaemia 2-3 weeks after start of treatment. Treatment of IV artesunate should be limited to the period that IV treatment is required and should be followed by a full oral course of an appropriate anti-malarial drug.read more
Citations
More filters
Journal ArticleDOI
A Continuous‐Flow Process for the Synthesis of Artemisinin
TL;DR: The synthetic continuous-flow process described here is an effective means to supplement the limited availability of artemisinin and ensure increased supplies of the drug for those in need.
Journal ArticleDOI
The geography of imported malaria to non-endemic countries: a meta-analysis of nationally reported statistics
Andrew J. Tatem,Peng Jia,Dariya Ordanovich,Michael Falkner,Zhuojie Huang,Rosalind E. Howes,Rosalind E. Howes,Simon I. Hay,Simon I. Hay,Peter W. Gething,David L. Smith,David L. Smith +11 more
TL;DR: This meta-analysis studied the database of publicly available nationally reported statistics on imported malaria in the past 10 years, covering more than 50 000 individual cases, to improve understanding of these phenomena and facilitate the design of mitigation strategies.
Journal ArticleDOI
Management of imported malaria in Europe
Helena H. Askling,Helena H. Askling,Fabrice Bruneel,Gerd D. Burchard,Francesco Castelli,Peter L. Chiodini,Martin P. Grobusch,Rogelio López-Vélez,Margaret Paul,Eskild Petersen,Corneliu Petru Popescu,Michael Ramharter,Patricia Schlagenhauf +12 more
TL;DR: In this position paper, the European Society for Clinical Microbiology and Infectious Diseases, Study Group on Clinical Parasitology, summarizes main issues regarding the management of imported malaria cases.
Journal ArticleDOI
Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins
Stéphane Jauréguiberry,Papa Alioune Ndour,Camille Roussel,Flavie Ader,Innocent Safeukui,Marie Nguyen,Sylvestre Biligui,Liliane Ciceron,Oussama Mouri,Eric Kendjo,François Bricaire,Muriel Vray,Adela Angoulvant,Julien Mayaux,Kasturi Haldar,Dominique Mazier,Martin Danis,Eric Caumes,Marc Thellier,Pierre Buffet +19 more
TL;DR: The findings consolidate a disease framework for posttreatment anemia in malaria in which delayed hemolysis is a new entity and the early concentration of once-infected erythrocytes is a solid candidate marker to predict post-AS delayed Hemolytic anemia.
Journal ArticleDOI
Delayed Hemolysis After Treatment With Parenteral Artesunate in African Children With Severe Malaria—A Double-center Prospective Study
Thierry Rolling,Tsiri Agbenyega,Saadou Issifou,Ayola A. Adegnika,Justice Sylverken,Dorothee Spahlinger,Daniel Ansong,Daniel Ansong,Sascha J Z Löhr,Gerd D. Burchard,Gerd D. Burchard,Jürgen May,Benjamin Mordmüller,Sanjeev Krishna,Peter G. Kremsner,Jakob P. Cramer,Jakob P. Cramer +16 more
TL;DR: Delayed hemolysis is a frequent and relevant complication in hyperparasitemic African children treated with parenteral artesunate for severe malaria and Physicians should be aware of this complication and consider prolonged follow-up.
References
More filters
Journal ArticleDOI
A method for estimating the probability of adverse drug reactions
Claudio A. Naranjo,Usoa E. Busto,Edward M. Sellers,Paul Sandor,I Ruiz,E A Roberts,E Janecek,Domecq C,David J. Greenblatt +8 more
TL;DR: It was shown that the ADR probability scale has consensual, content, and concurrent validity and may be applicable to postmarketing drug surveillance.
Journal ArticleDOI
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.
TL;DR: Artesunate should become the treatment of choice for severe falciparum malaria in adults because it is more rapidly acting than intravenous quinine in terms of parasite clearance and is simpler to administer.
Journal ArticleDOI
Qinghaosu (artemisinin): the price of success.
TL;DR: Artemisinin combination treatments are now first-line drugs for uncomplicated falciparum malaria, but access to ACTs is still limited in most malaria-endemic countries and a global subsidy would make these drugs more affordable and available.
Journal ArticleDOI
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.
Arjen M. Dondorp,Caterina I. Fanello,Ilse C. E. Hendriksen,Ermelinda Gomes,Amir Seni,Kajal D. Chhaganlal,Kalifa Bojang,Rasaq Olaosebikan,Nkechinyere Anunobi,Kathryn Maitland,Esther Kivaya,Tsiri Agbenyega,Samuel Blay Nguah,Jennifer R Evans,Samwel Gesase,Catherine Kahabuka,George Mtove,Behzad Nadjm,Jacqueline L. Deen,Juliet Mwanga-Amumpaire,Margaret Nansumba,Corine Karema,Noella Umulisa,Aline Uwimana,Olugbenga A. Mokuolu,Olanrewaju T. Adedoyin,W B Johnson,Antoinette Tshefu,Marie A. Onyamboko,Tharisara Sakulthaew,Wirichada Pan Ngum,Kamolrat Silamut,Kasia Stepniewska,Charles J. Woodrow,D. Bethell,Bridget Wills,Martina Oneko,Tim E. A. Peto,Lorenz von Seidlein,Nicholas P. J. Day,Nicholas J. White +40 more
TL;DR: Parenteral artesunate should replace quinine as the treatment of choice for severe falciparum malaria worldwide, according to evidence from Asia, and substantially reduces mortality in African children with severe malaria.
Journal ArticleDOI
Evaluation of In-Hospital Management for Febrile Illness in Northern Tanzania before and after 2010 World Health Organization Guidelines for the Treatment of Malaria
Andrew M. Moon,Holly M. Biggs,Matthew P. Rubach,John A. Crump,Venace P. Maro,Venace P. Maro,Wilbrod Saganda,Elizabeth A. Reddy +7 more
TL;DR: Differences in historic and recent hospital cohorts in the diagnosis and treatment of febrile illness in a low malaria prevalence area of northern Tanzania are assessed to assess changes in the treatment of malaria and bacterial infections.
Related Papers (5)
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.
Arjen M. Dondorp,Caterina I. Fanello,Ilse C. E. Hendriksen,Ermelinda Gomes,Amir Seni,Kajal D. Chhaganlal,Kalifa Bojang,Rasaq Olaosebikan,Nkechinyere Anunobi,Kathryn Maitland,Esther Kivaya,Tsiri Agbenyega,Samuel Blay Nguah,Jennifer R Evans,Samwel Gesase,Catherine Kahabuka,George Mtove,Behzad Nadjm,Jacqueline L. Deen,Juliet Mwanga-Amumpaire,Margaret Nansumba,Corine Karema,Noella Umulisa,Aline Uwimana,Olugbenga A. Mokuolu,Olanrewaju T. Adedoyin,W B Johnson,Antoinette Tshefu,Marie A. Onyamboko,Tharisara Sakulthaew,Wirichada Pan Ngum,Kamolrat Silamut,Kasia Stepniewska,Charles J. Woodrow,D. Bethell,Bridget Wills,Martina Oneko,Tim E. A. Peto,Lorenz von Seidlein,Nicholas P. J. Day,Nicholas J. White +40 more
Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins
Stéphane Jauréguiberry,Papa Alioune Ndour,Camille Roussel,Flavie Ader,Innocent Safeukui,Marie Nguyen,Sylvestre Biligui,Liliane Ciceron,Oussama Mouri,Eric Kendjo,François Bricaire,Muriel Vray,Adela Angoulvant,Julien Mayaux,Kasturi Haldar,Dominique Mazier,Martin Danis,Eric Caumes,Marc Thellier,Pierre Buffet +19 more